SCYX Q3 2024 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$660,000-62.5% YoY

Gross Profit

$660,000100.0% margin

Operating Income

-$10M-1563.6% margin

Net Income

-$3M-425.5% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

-10.3%

Cash Flow

Operating Cash Flow

$765,000

Free Cash Flow

$765,000

Stock-Based Comp.

$901,000

Balance Sheet

Total Assets

$99M

Total Liabilities

$41M

Stockholders' Equity

$59M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$660,000	$2M	-62.5%
Gross Profit	$660,000	$1M	-52.2%
Operating Income	-$10M	-$10M	-2.2%
Net Income	-$3M	-$2M	-59.8%

Revenue Segments

License and Service

$660,000100%